The Protein Sequencing Companytm, and several distinguished researchers will highlight advances in Next-Generation Protein Sequencingtm (NGPStm) at the US Human Proteome ...

In a strong validation of the company’s clinical trial, Imugene Ltd’s Phase 1b trial for its azer-cel off-the-shelf, allogeneic, CD19 CAR T therapy in relapsed/refractory diffuse large B-cell lymphoma ...

Recursion is advancing REC-617, a promising reversible, non-covalent CDK7 inhibitor, showing potential in treating advanced solid tumors with positive interim phase 1 data. Read more here.

"Net sales increased during the fourth quarter by 41.5 percent to SEK 64.2 million, compared with the corresponding quarter of 2023. The growth and strong performance are a result of robust developmen ...

Blueprint Medicines Corporation ( NASDAQ: BPMC) Q4 2024 Earnings Conference Call February 13, 2025 8:00 AM ET ...

New Data at ASCO GU Show Power of Veracyte’s Decipher Tests to Improve Patient Care and Its GRID Tool to Advance Prostate and ...

These work particularly well for websites, brochures, and presentations. Example: A clean, simple timeline of career highlights can demonstrate progression and credibility without overwhelming the ...

Experts discuss how cancer treatment and survivorship can be made more equitable and affordable through advocacy, outreach, and effective communication tools. Beyond Cancer: Caring for Young ...

Implantica reported a mixed financial performance for Q4 2024, with a 30% year-over-year decrease in quarterly revenue to €442,000, while full-year net sales rose by 38% to €1.9 million. The company's ...

Visit us on Facebook. Opens in a new tab or window Visit us on X. Opens in a new tab or window Visit us on Instagram. Opens in a new tab or window Visit us on LinkedIn. Opens in a new tab or ...

Blueprint Medicines Corp (NASDAQ:BPMC) reported a challenging fourth quarter for 2024, missing analyst expectations for both earnings per share (EPS) and revenue. The company posted an EPS of -0.79, ...

Although the treatment of myeloma has changed dramatically after the readout of many recent trials, key unanswered questions remain.